A Novel Mutation in NDUFS4 Causes Leigh Syndrome in an Ashkenazi Jewish Family

Total Page:16

File Type:pdf, Size:1020Kb

A Novel Mutation in NDUFS4 Causes Leigh Syndrome in an Ashkenazi Jewish Family J Inherit Metab Dis (2008) 31 (Suppl 2):S461–S467 DOI 10.1007/s10545-008-1049-9 SHORT REPORT A novel mutation in NDUFS4 causes Leigh syndrome in an Ashkenazi Jewish family S. L. Anderson & W. K. Chung & J. Frezzo & J. C. Papp & J. Ekstein & S. DiMauro & B. Y. Rubin Received: 15 September 2008 /Submitted in revised form: 13 November 2008 /Accepted: 19 November 2008 / Published online: 26 December 2008 # SSIEM and Springer 2008 Summary Leigh syndrome is a neurodegenerative without consanguinity with three affected children. disorder of infancy or childhood generally due to Linkage to microsatellite markers D5S1969 and mutations in nuclear or mitochondrial genes involved D5S407 led to evaluation of the complex I gene in mitochondrial energy metabolism. We performed NDUFS4, in which we identified a novel homozygous linkage analysis in an Ashkenazi Jewish (AJ) family c.462delA mutation that disrupts the reading frame. The resulting protein lacks a cAMP-dependent protein kinase phosphorylation site required for activation of Communicating editor: John Christodoulou mitochondrial respiratory chain complex I. In a Competing interests: None declared random sample of 5000 healthy AJ individuals, the References to electronic databases: Leigh syndrome: OMIM carrier frequency of the NDUFS4 mutation c.462delA 256000. NDUFS4: OMIM 602694. NDUFS4 mRNA: GenBank was 1 in 1000, suggesting that it should be considered accession # NM_002495. : : in all AJ patients with Leigh syndrome. S. L. Anderson J. Frezzo B. Y. Rubin (*) Department of Biological Sciences, Fordham University, Abbreviations 441 E. Fordham Rd., Bronx, NY 10458, USA AJ Ashkenazi Jewish e-mail: [email protected] BCS1L BCS1-like protein W. K. Chung DLD dihydrolipoamide dehydrogenase Department of Pediatrics, MRS magnetic resonance spectroscopy Columbia University Medical Center, NDUFs NADH-ubiquinone oxidoreductase New York, New York, USA Fe-S proteins and flavoproteins J. C. Papp PDHC pyruvate dehydrogenase complex Department of Human Genetics, University of California, RT-PCR reverse transcription polymerase chain Los Angeles, California, USA reaction J. Ekstein SDHA succinate dehydrogenase complex, Dor Yeshorim, The Committee for Prevention subunit A of Jewish Genetic Diseases, SURF1 surfeit 1 Brooklyn, New York, USA J. Ekstein Dor Yeshorim, The Committee for Prevention of Jewish Genetic Diseases, Introduction Jerusalem, Israel Leigh syndrome (OMIM 256000), or subacute necro- S. DiMauro tizing encephalomyelopathy, is a devastating, pae- Department of Neurology, Columbia University Medical Center, diatric neurodegenerative disorder characterized by New York, New York, USA bilateral, symmetric lesions in the brainstem, midbrain, S462 J Inherit Metab Dis (2008) 31 (Suppl 2):S461–S467 pons, thalamus, basal ganglia, and cerebellum (Leigh NM_002495). We demonstrate that the c.462delA 1951). Individuals with Leigh syndrome present with NDUFS4 mutation represents an AJ founder mutation variable clinical symptoms that include hypotonia, with a carrier frequency of approximately 1 in 1000. psychomotor retardation or regression, respiratory Identification of this AJ founder mutation should difficulties, recurrent vomiting, nystagmus, ataxia, facilitate genetic evaluation of Leigh syndrome in AJ peripheral neuropathy, external ophthalmoplegia, loss families. of vision, impaired hearing, and seizures (Loeffen et al 2000; Pitkanen et al 1996). Laboratory investigations often reveal elevated lactate levels in blood and Case reports cerebral spinal fluid. Leigh syndrome is associated with progressive neurological dysfunction and is usu- Case 1 ally lethal within the first two years of life. Biochem- ically, Leigh syndrome can result from a number of The proband, a male infant, presented at 3.5 months of inherited defects in mitochondrial energy metabolism. age with strabismus, difficulty gaining weight and Genetically, Leigh syndrome can be autosomal reces- irritability. Neurological examination showed hypoto- sive, X linked, or maternally inherited, and can result nia, head lag, ptosis and strabismus. MRI of the brain from mutations in genes encoding subunits of the demonstrated bilateral symmetrical T2 signal abnor- pyruvate dehydrogenase complex (PDHC) or subunits malities in the cerebral peduncles, red nuclei, pons and of respiratory chain complexes I, II, III, IV or V, but medulla. Magnetic resonance spectroscopy (MRS) predominantly of complexes I and IV (DiMauro and showed increased lactate and decreased N-acetylas- Schon 2001; Kirby et al 1999; Loeffen et al 2000; partic acid. MRI and MRS results suggested the Robinson 1998). Complex I is a large multiprotein diagnosis of Leigh syndrome. His prenatal history enzyme complex that transports electrons from was unremarkable. He was the product of a 41-week NADH to ubiquinone as protons are shuttled across gestation, born via normal spontaneous vaginal deliv- the inner mitochondrial membrane into the inter- ery to a 37-year-old G1P0 mother with a birth weight membrane space. Complex I is composed of seven of 3436 g and head circumference of 32 cm. His Apgar mitochondrial DNA-encoded proteins and 39 nuclear- scores were 9 and 9 at 1 and 5 minutes. At 6 months of encoded subunits (Carroll et al 2003). Mutations have age, he was admitted to the hospital for failure to been identified in all seven mitochondrial DNA- thrive and received nasogastric tube feeds. During the encoded subunits and in the nuclear genes encoding hospitalization, he was found unresponsive, required the NADH-ubiquinone oxidoreductase Fe-S proteins intubation, and could not be extubated thereafter. His and flavoproteins (NDUFs) NDUFS1, NDUFS2, clinical course was progressive and characterized by NDUFS4, NDUFS7, NDUFS8, NDUFV1 and failure to thrive and decreased gut motility that NDUFV2 (Benit et al 2001, 2003a, b; Budde et al required a gastrostomy-jejunostomy feeding tube. His 2000; Loeffen et al 1998, 2001; Petruzzella et al 2001; persistent respiratory insufficiency required a trache- Schuelke et al 1999; Triepels et al 1999; van den ostomy and ventilator support. He also developed a Heuvel et al 1998). Mutations in NDUFS1, NDUFS4, hypertrophic cardiomyopathy with moderate concen- NDUFS7, NDUFS8 and NDUFV1 have been reported tric hypertrophy and qualitatively good biventricular to cause Leigh syndrome or Leigh syndrome-like systolic function. He had recurrent unexplained fevers disease (Benit et al 2001; Budde et al 2000; Loeffen and sustained hypertension, presumably secondary to et al 1998; Petruzzella et al 2001; Schuelke et al 1999; autonomic dysfunction. Neurologically, he regressed Triepels et al 1999; van den Heuvel et al 1998), while developmentally and became less responsive and more mutations in NDUFS2 and NDUFV2 have been hypotonic despite treatment with coenzyme Q10, associated with cardiomyopathy and encephalomyop- L-carnitine, thiamine and sodium citrate. Multiple athy (Benit et al 2003a; Loeffen et al 2001). The electroencephalograms demonstrated mild to moder- identification of mutations causing complex I defects ate diffuse slowing without evidence of seizures, has been hampered by the large number of proteins in indicating an encephalopathy with diffuse cerebral this complex and by the limited understanding of the dysfunction. At 10 months of age, he died at home. role of each component. Family history at the time was unremarkable. He had a We describe an Ashkenazi Jewish (AJ) family with 13-year-old paternal half brother and a 10-year-old three affected children with Leigh syndrome and paternal half-sister who were both healthy. Both his harbouring a homozygous c.462delA mutation in parents were Ashkenazi Jews. There was no known NDUFS4 (OMIM 602694; GenBank accession no. history of consanguinity. There was no maternal or J Inherit Metab Dis (2008) 31 (Suppl 2):S461–S467 S463 Table 1 Activities of mitochondrial enzymes in skeletal muscle biopsy in a 10% muscle homogenate Enzyme Complex Activity Control activity T standard (mmol/min per g) deviation (mmol/min per g) Cytochrome-c oxidase IV 3.85 2.80 T 0.52 Succinate cytochrome-c reductase II + III 0.72 0.70 T 0.23 NADH cytochrome-c reductase I + III 0.59 1.02 T 0.38 NADH dehydrogenase I 31.36 35.48 T 7.07 Citrate synthase 17.22 9.88 T 2.55 Succinate dehydrogenase 1.67 1.00 T 0.53 paternal family history of childhood deaths, seizures, exotropia and irritability and was hypotonic. MRI of mental retardation, stroke, blindness, hearing loss, the brain demonstrated symmetric areas of signal diabetes or cardiomyopathy. hyperintensity on T2-weighted images in the cerebral His metabolic evaluation was significant for a peduncles, periaqueductal regions of the midbrain, plasma lactate that ranged from 1.0 to 9.5 mmol/L dorsal pontomedullary junction, corpus callosum, and (normal, <2.2) over a 4-month period, plasma lactate: medial globus pallidus. At 6 months of age, a gastro- pyruvate ratio of 22 (normal <25) measured simulta- stomy tube was placed to assist with feeding, and she neously when the cerebrospinal fluid lactate was 4.5 died two days later with lactic acidosis. mmol/L (normal <2.2) and cerebrospinal fluid pyru- Triplet B (case 3) presented at 6 months of age with vate was 0.17 mmol/L (normal <0.13). A muscle biopsy exotropia, hypotonia and poor head control. Unlike his at 5 months of age demonstrated a few atrophic previously two affected siblings, by 5–6 months of age fibres without ragged-red fibres, COX-deficient he was able to roll over and he was more active. He fibres, or mitochondrial
Recommended publications
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • Progressive Encephalopathy and Central Hypoventilation Related to Homozygosity of NDUFV1 Nuclear Gene, a Rare Mitochondrial Disease
    Avens Publishing Group Inviting Innovations Open Access Case Report J Pediatr Child Care August 2019 Volume:5, Issue:1 © All rights are reserved by AL-Buali MJ, et al. AvensJournal Publishing of Group Inviting Innovations Progressive Encephalopathy Pediatrics & and Central Hypoventilation Child Care AL-Buali MJ*, Al Ramadhan S, Al Buali H, Al-Faraj J and Related to Homozygosity of Al Mohanna M Pediatric Department , Maternity Children Hospital , Saudi Arabia *Address for Correspondence: NDUFV1 Nuclear Gene, a Rare Al-buali MJ, Pediatric Consultant and Consultant of Medical Genetics, Deputy Chairman of Medical Genetic Unite, Pediatrics Department , Maternity Children Hospital, Al-hassa, Hofuf city, Mitochondrial Disease Saudi Arabia; E-mail: [email protected] Submission: 15 July 2019 Accepted: 5 August 2019 Keywords: Progressive encephalopathy; Central hypoventilation; Published: 9 August 2019 Nuclear mitochondrial disease; NDUFV1 gene Copyright: © 2019 AL-Buali MJ, et al. This is an open access article distributed under the Creative Commons Attribution License, which Abstract permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background: Mitochondrial diseases are a group of disorders caused by dysfunctional organelles that generate energy for our body. Mitochondria small double-membrane organelles found in of the most common groups of genetic diseases with a minimum every cell of the human body except red blood cells. Mitochondrial diseases are sometimes caused by mutations in the mitochondrial DNA prevalence of greater than 1 in 5000 in adults. Mitochondrial diseases that affect mitochondrial function. Other mitochondrial diseases are can be present at birth but can be manifested also at any age [2].
    [Show full text]
  • High-Throughput, Pooled Sequencing Identifies Mutations in NUBPL And
    ARTICLES High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency Sarah E Calvo1–3,10, Elena J Tucker4,5,10, Alison G Compton4,10, Denise M Kirby4, Gabriel Crawford3, Noel P Burtt3, Manuel Rivas1,3, Candace Guiducci3, Damien L Bruno4, Olga A Goldberger1,2, Michelle C Redman3, Esko Wiltshire6,7, Callum J Wilson8, David Altshuler1,3,9, Stacey B Gabriel3, Mark J Daly1,3, David R Thorburn4,5 & Vamsi K Mootha1–3 Discovering the molecular basis of mitochondrial respiratory chain disease is challenging given the large number of both mitochondrial and nuclear genes that are involved. We report a strategy of focused candidate gene prediction, high-throughput sequencing and experimental validation to uncover the molecular basis of mitochondrial complex I disorders. We created seven pools of DNA from a cohort of 103 cases and 42 healthy controls and then performed deep sequencing of 103 candidate genes to identify 151 rare variants that were predicted to affect protein function. We established genetic diagnoses in 13 of 60 previously unsolved cases using confirmatory experiments, including cDNA complementation to show that mutations in NUBPL and FOXRED1 can cause complex I deficiency. Our study illustrates how large-scale sequencing, coupled with functional prediction and experimental validation, can be used to identify causal mutations in individual cases. Complex I of the mitochondrial respiratory chain is a large ~1-MDa ­assembly factors are probably required, as suggested by the 20 factors macromolecular machine composed of 45 protein subunits encoded necessary for assembly of the smaller complex IV9 and by cohort by both the nuclear and mitochondrial (mtDNA) genomes.
    [Show full text]
  • A Minimum-Labeling Approach for Reconstructing Protein Networks Across Multiple Conditions
    A Minimum-Labeling Approach for Reconstructing Protein Networks across Multiple Conditions Arnon Mazza1, Irit Gat-Viks2, Hesso Farhan3, and Roded Sharan1 1 Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv 69978, Israel. Email: [email protected]. 2 Dept. of Cell Research and Immunology, Tel Aviv University, Tel Aviv 69978, Israel. 3 Biotechnology Institute Thurgau, University of Konstanz, Unterseestrasse 47, CH-8280 Kreuzlingen, Switzerland. Abstract. The sheer amounts of biological data that are generated in recent years have driven the development of network analysis tools to fa- cilitate the interpretation and representation of these data. A fundamen- tal challenge in this domain is the reconstruction of a protein-protein sub- network that underlies a process of interest from a genome-wide screen of associated genes. Despite intense work in this area, current algorith- mic approaches are largely limited to analyzing a single screen and are, thus, unable to account for information on condition-specific genes, or reveal the dynamics (over time or condition) of the process in question. Here we propose a novel formulation for network reconstruction from multiple-condition data and devise an efficient integer program solution for it. We apply our algorithm to analyze the response to influenza in- fection in humans over time as well as to analyze a pair of ER export related screens in humans. By comparing to an extant, single-condition tool we demonstrate the power of our new approach in integrating data from multiple conditions in a compact and coherent manner, capturing the dynamics of the underlying processes. 1 Introduction With the increasing availability of high-throughput data, network biol- arXiv:1307.7803v1 [q-bio.QM] 30 Jul 2013 ogy has become the method of choice for filtering, interpreting and rep- resenting these data.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • In Vitro Treatment of Hepg2 Cells with Saturated Fatty Acids Reproduces
    © 2015. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2015) 8, 183-191 doi:10.1242/dmm.018234 RESEARCH ARTICLE In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis Inmaculada García-Ruiz1,*, Pablo Solís-Muñoz2, Daniel Fernández-Moreira3, Teresa Muñoz-Yagüe1 and José A. Solís-Herruzo1 ABSTRACT INTRODUCTION Activity of the oxidative phosphorylation system (OXPHOS) is Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of decreased in humans and mice with nonalcoholic steatohepatitis. liver diseases extending from pure fatty liver through nonalcoholic Nitro-oxidative stress seems to be involved in its pathogenesis. The steatohepatitis (NASH) to cirrhosis and hepatocarcinoma that occurs aim of this study was to determine whether fatty acids are implicated in individuals who do not consume a significant amount of alcohol in the pathogenesis of this mitochondrial defect. In HepG2 cells, we (Matteoni et al., 1999). Although the pathogenesis of NAFLD analyzed the effect of saturated (palmitic and stearic acids) and remains undefined, the so-called ‘two hits’ model of pathogenesis monounsaturated (oleic acid) fatty acids on: OXPHOS activity; levels has been proposed (Day and James, 1998). Whereas the ‘first hit’ of protein expression of OXPHOS complexes and their subunits; gene involves the accumulation of fat in the liver, the ‘second hit’ expression and half-life of OXPHOS complexes; nitro-oxidative stress; includes oxidative stress resulting in inflammation, stellate cell and NADPH oxidase gene expression and activity. We also studied the activation, fibrogenesis and progression of NAFLD to NASH effects of inhibiting or silencing NADPH oxidase on the palmitic-acid- (Chitturi and Farrell, 2001).
    [Show full text]
  • Proteomic and Metabolomic Analyses of Mitochondrial Complex I-Deficient
    THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 24, pp. 20652–20663, June 8, 2012 © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. Proteomic and Metabolomic Analyses of Mitochondrial Complex I-deficient Mouse Model Generated by Spontaneous B2 Short Interspersed Nuclear Element (SINE) Insertion into NADH Dehydrogenase (Ubiquinone) Fe-S Protein 4 (Ndufs4) Gene*□S Received for publication, November 25, 2011, and in revised form, April 5, 2012 Published, JBC Papers in Press, April 25, 2012, DOI 10.1074/jbc.M111.327601 Dillon W. Leong,a1 Jasper C. Komen,b1 Chelsee A. Hewitt,a Estelle Arnaud,c Matthew McKenzie,d Belinda Phipson,e Melanie Bahlo,e,f Adrienne Laskowski,b Sarah A. Kinkel,a,g,h Gayle M. Davey,g William R. Heath,g Anne K. Voss,a,h René P. Zahedi,i James J. Pitt,j Roman Chrast,c Albert Sickmann,i,k Michael T. Ryan,l Gordon K. Smyth,e,f,h b2 a,h,m,n3 David R. Thorburn, and Hamish S. Scott Downloaded from From the aMolecular Medicine Division, gImmunology Division, and eBioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia, the bMurdoch Childrens Research Institute, Royal Children’s Hospital and Department of Paediatrics, University of Melbourne, Parkville, Victoria 3052, Australia, the cDépartement de Génétique Médicale, Université de Lausanne, 1005 Lausanne, Switzerland, the dCentre for Reproduction and Development, Monash Institute of Medical Research, Clayton, Victoria 3168, Australia, the hDepartment of Medical Biology
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • Low Abundance of the Matrix Arm of Complex I in Mitochondria Predicts Longevity in Mice
    ARTICLE Received 24 Jan 2014 | Accepted 9 Apr 2014 | Published 12 May 2014 DOI: 10.1038/ncomms4837 OPEN Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice Satomi Miwa1, Howsun Jow2, Karen Baty3, Amy Johnson1, Rafal Czapiewski1, Gabriele Saretzki1, Achim Treumann3 & Thomas von Zglinicki1 Mitochondrial function is an important determinant of the ageing process; however, the mitochondrial properties that enable longevity are not well understood. Here we show that optimal assembly of mitochondrial complex I predicts longevity in mice. Using an unbiased high-coverage high-confidence approach, we demonstrate that electron transport chain proteins, especially the matrix arm subunits of complex I, are decreased in young long-living mice, which is associated with improved complex I assembly, higher complex I-linked state 3 oxygen consumption rates and decreased superoxide production, whereas the opposite is seen in old mice. Disruption of complex I assembly reduces oxidative metabolism with concomitant increase in mitochondrial superoxide production. This is rescued by knockdown of the mitochondrial chaperone, prohibitin. Disrupted complex I assembly causes premature senescence in primary cells. We propose that lower abundance of free catalytic complex I components supports complex I assembly, efficacy of substrate utilization and minimal ROS production, enabling enhanced longevity. 1 Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE4 5PL, UK. 2 Centre for Integrated Systems Biology of Ageing and Nutrition, Newcastle University, Newcastle upon Tyne NE4 5PL, UK. 3 Newcastle University Protein and Proteome Analysis, Devonshire Building, Devonshire Terrace, Newcastle upon Tyne NE1 7RU, UK. Correspondence and requests for materials should be addressed to T.v.Z.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]